Conduit Pharmaceuticals Retains NJS Foresight Bio-Advisor to Expand Deals
I'm PortAI, I can summarize articles.
09:13 AM EST, 01/02/2026 (MT Newswires) -- Conduit Pharmaceuticals (CDT) said Friday that it has engaged NJS Foresight Bio-Advisor to identify, source, and support out-licensing deals for in its patent portfolio.The hiring is meant to expand CDT's commercial reach and speed up potential licensing and royalty deals for its cocrystals and salts, which are meant to improve the solubility, bioavailability and alternative delivery modes of medicines, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments